Trastuzumab for HER-2-Positive Advanced Salivary Gland Cancer

Trastuzumab治療晚期第二型人類表皮生長因子受體表現陽性的唾液腺癌

楊鎰聰(Yi-Tsung Yang) ； 洪瑞隆(Ruey-Long Hong)

《台灣癌症醫學雜誌》 1卷3期 (2014/12) Pp. 220-225

https://doi.org/10.6323/JCRP.2014.1.3.05

摘要

唾液腺腺癌是頭頸部一種少見的腫瘤，具有復發及轉移的潛在特性，所以常被視為高惡性度。由於臨床病例不多，目前並無標準的治療方式，但開刀切除是在疾病早期可切除時的主要治療方式，且常在開刀後建議輔以放射線治療。全身性化學治療常保留給晚期轉移性的病患上，且治療的成績往往不夠理想。隨著分子醫學的進步，唾液腺癌被發現經常帶有多種分子的變異，可供治療的標的。我們在此提出一個案例報告，這是一個67歲男性病患，診斷為第二型人類表皮生長因子受體表現陽性的轉移性唾液腺癌，在使用含有trastuzumab的處方治療後，成功有效地控制腫瘤的生長。

關鍵字

賀癌平 ； 唾液腺癌 ； 第二型人類表皮生長因子受體

並列摘要

Salivary gland adenocarcinoma is a rare type of head and neck cancer and often has aggressive behavior with propensity to recur and metastasize. Currently, there are no standard treatment guidelines. Surgery is however, the mainstay of treatment in resectable disease and radiation is also considered for most patients after surgery. Systemic chemotherapy is reserved for metastatic cases, but its results are often disappointing. Recent development of molecular biology has shown that salivary gland caner has several molecular changes which may guide potential therapeutic targets. Here, we report a 67 year-old man diagnosed to have metastasized minor salivary gland adenocarcinoma with diffuse human epidermal growth factor receptor-2 (HER-2)-positive, by the immunohistochemical (IHC) stain. He was treated with a trastuzumabcontaining chemotherapeutic regimen with encouraging results.

並列關鍵字

trastuzumab ； salivary gland cancer ； HER-2